# A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

> **NCT01156961** · PHASE4 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01156961
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Absence of patient's recruitment in the study due to administrative reasons
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156961, "A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01156961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*